Results from a published multicenter study
The results from a German multicenter study were published in the latest issue of Tumor Biology. Principal investigator was Dr Thorsten Ecke at the Department of Urology, HELIOS Hospital, Bad Saarow.
Urine samples were analyzed with UBC® Rapid POC test and results were determined quantitatively with a reader.
Bladder cancer is one of the most costly cancer diseases, affecting around 2500 persons yearly in Sweden.
The most common method for detection of bladder cancer and for the assessment of recurrence is cystoscopy, a procedure in which an optic fiber is used for examination of the bladder.
The Swedish company IDL Biotech AB has developed a complementary test to cystoscopy – UBC® Rapid, especially useful for detection of high grade bladder cancer.
The test is already clinically documented and is in routine use in Germany.
The combination of UBC® Rapid with an objective POC-reader can enable improved risk stratification.
The new study demonstrated a very high sensitivity (71%) and specificity (94%)for high grade tumors. For patients with cancer in situ (CIS), the sensitivity was even higher (87%). The authors conclude that UBC® Rapid should be added in the diagnostics of high grade tumors and especially for CIS patients.